Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humacyte Inc.

This article was originally published in Start Up

Executive Summary

Humacyte uses smooth muscle cells isolated from cadavers to create a collagen matrix. The cells are grown on a biodegradable scaffold for 8-10 weeks. The original scaffold degrades, leaving just the cells and the collagen matrix. In a final step, researchers remove the cells and leave only the matrix. Without the cells, the non-immunogenic matrix can be used as a 'universal' off-the-shelf medical device. It can be grown in tube, sheet, or particulate form. Once implanted, host cells infiltrate, which then integrate and remodel the graft as if it were a natural body part.
Advertisement

Related Content

Scaffolds in Tissue Engineering
Start-Up Previews (02/2008)
Scaffolds in Tissue Engineering
Start-Up Previews (02/2008)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel